HORMONAL IMBALANCE OF THE PITUITARY AND OVARIAN SYSTEM IN WOMEN WITH ENDOMETRIAL HYPERPLASIA AND BENIGN TUMOR OF THE MAMMARY GLANDS

Shapoval Yu. S.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Transformation of endometrial cells and mammary gland cells occurs under the influence of altered ratios of hormones of the pituitary-ovarian system, which leads to changes in the morphological structure of these organs. Hyperplastic processes in the endometrium are one of the causes of infertility in women of childbearing age, which makes it important to study this problem. Purpose: to determine the level of ovarian and pituitary hormones in the blood plasma of women of reproductive age under conditions of development in the body of various types of endometrial hyperplasia and benign breast tumors. Object and methods of research. Surveys of women of reproductive age were conducted, which were divided into: the comparison group – women with GPE, and the main group – women with GPE and benign diseases of the breast. The analysis of indicators was performed taking into account the type of endometrial hyperplasia – GPE without atypia, atypical GPE and endometrial polyps. The condition of the pituitary-ovarian system was assessed by determining the hormones of the reproductive panel (follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen and progesterone). Levels of pituitary and ovarian hormones were determined using test kits for enzyme-linked immunosorbent assay. Results. It was found that the main endocrine disorder in GPE and proliferative dysplasia of the mammary glands is a hormonal imbalance with a predominance of hyperestrogenism and decreased progesterone levels. The greatest violations occur in atypical endometrial hyperplasia. It is shown that changes in pituitary hormones in GPE are manifested by an increase in plasma of both FSH and LH. Along with this, there is a decrease in the ratio of LH / FSH, which indicates the predominance of FSH products. Conclusions. In women with GPE and benign neoplasms of the mammary glands, there is an imbalance of hormones of the pituitary-ovarian system, which is expressed by relative hyperestrogenism, progesterone deficiency, elevated levels of FSH and LH, but a decrease in the ratio of LH / FSH. These changes are exacerbated in patients with atypical endometrial hyperplasia.

endometrial hyperplasia, mastopathy, estrogen, progesterone, follicle-stimulating hormone, luteinizing hormone.

1. Nikitina IM, Horban NY, Mykytyn KV, Kondratiuk KO, Smiian SA, Kalashnyk NV, et al. The state of reproductive health of women with hyperproliferative pathology of the endometrium. Wiad Lek. 2021;74(9.1):2076–2081.
2. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232–254. DOI: 10.1093/humupd/dmw042.
3. Zhou X, Xu Y, Yin D, Zhao F, Hao Z, Zhong Y, et al. Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O‑glycosylating enzyme GALNT2. Biomed Pharmacother. 2020;131:110764. DOI: 10.1016/j.biopha.2020.110764.
4. Sebastian A, Neerudu SR, Rebekah G, Varghese L, Regi A, Thomas A, et al. Risk factors for endometrial carcinoma in women with postmenopausal bleeding. J Obstet Gynaecol India. 2021;71(4):417–423. DOI: 10.1007/s13224–021–01464–3.
5. Wilczyński M, Domańska-­Senderowska D, Kassassir-­Ćwiklak SA, Janas Ł, Malinowski A, Wilczyński JR. A body shape index (ABSI) and endometrial pathology. Women Health. 2021;61(3):313–321. DOI: 10.1080/03630242. 2021.1881697.
6. Emons G, Gründker C. The role of gonadotropin-­releasing hormone (GnRH) in endometrial cancer. Cells. 2021;10(2):292. DOI: 10.3390/cells10020292.
7. Rahnama R, Mahmoudi AR, Kazemnejad S, Salehi M, Ghahiri A, Soltanghoraee H, et al. Thyroid peroxidase in human endometrium and placenta: a potential target for anti-­TPO antibodies. Clin Exp Med. 2021;21(1):79–88. DOI: 10.1007/s10238–020–00663-y.
8. Baker JM, Al-­Nakkash L, Herbst-­Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45–53. DOI: 10.1016/j.maturitas.
9. Franzen A, Greene T, Van Landingham C, Gentry R. Toxicology of octamethylcyclotetrasiloxane (D 4). Toxicol Lett. 2017;279(1):2– 22. DOI: 10.1016/j.toxlet.2017.06.007.
10. Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen receptor function: impact on the human endometrium. Front Endocrinol (Lausanne). 2022;13:827724. DOI: 10.3389/fendo.2022.827724.
11. Li C, Xing C, Zhang J, Zhao H, Shi W, He B. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Transl Med. 2021;19(1):148. DOI: 10.1186/s12967–021–02817–2.
12. Wong YJ, Gold EB, Johnson WO, Lee JS. Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women’s Health Across the Nation (SWAN). J. Clinical Endocrinology & Metabolism. 2016;101(1):123–130. DOI: 10.1210/jc.2015–2935.
13. Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44–9. DOI: 10.1007/ s11102–011–0339–7.
14. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med. 2020;38(2– 03):129–143. DOI: 10.1055/s‑0040–1716687.
15. Devis-­Jauregui L, Eritja N, Davis ML, Matias-­Guiu X, Llobet-­Navàs D. Autophagy in the physiological endometrium and cancer. Autophagy. 2021;17(5):1077–1095. DOI: 10.1080/15548627.2020.1752548.
16. Boichuk AV, Shadrina VS, Vereshchahina TV. Hyperplasia of endometrium – a modern system-­pathogenetic view on the problem (literature review). Actual problems of pediatrics, obstetrics and gynecology. 2019;1:67–72.

«Bulletin of problems biology and medicine» Issue 2 Part 1 (164), 2022 year, 264-275 pages, index UDK 618.19–006.03:618.14:611.664:618.11:616.432–002

10.29254/2077-4214-2022-2-1-164-264-275